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dosage) and presenteeism (work capacity; 0-100%). Participants
were also asked to report occasions of absenteeism and use of
health care services in the past two months. The methods used
before and during the trial to encourage correct completion and
timely return included: restriction of the diary to one colourful
page, piloting among patient and non-patient groups during the
development process, provision of a study magnet for attachment
to a kitchen appliance, feedback on diary completion during the
pre-randomisation run-in, and verbal encouragement during the
bimonthly participant retention telephone calls. Acceptability of
this novel measurement tool was evaluated by return of a correctly
completed Participant Diary within one month of despatch.
Results: At the end of 2008, 317 participants had been ran-
domised for more than one month. Of these, 285 (90%) had
returned a correctly completed ﬁrst Participant Diary (sent at the
time of randomisation) within one month. At the end of October
2008, 245 patients had been randomised more than 3 months.
Of these, 211 (86%) had returned the second Participant Diary.
Similarly, the return rate of the third and fourth Participant Diaries
was 156/184 (85%) and 92/112 (82%), respectively. Participants
dropping out of the study are included in the denominator of these
calculations.
Conclusions: A long development process and regular highlight-
ing/reinforcement of the importance of diary return during routine
telephone calls resulted in very high completion and return rates,
thereby demonstrating acceptability of this tool.This Participant
Diary is able to regularly capture, at low cost, important clinical
and health economic outcomes during the course of a long-term
clinical trial among people with symptomatic knee OA.
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MAGNETIC RESONANCE IMAGING: AN OPEN-LABEL PILOT
STUDY EVALUATING THE DISEASE MODIFYING EFFECT OF
CELECOXIB COMPARED TO A MODELIZED HISTORICAL
CONTROL COHORT IN KNEE OSTEOARTHRITIS
J.-P. Raynauld1, J. Martel-Pelletier1, A. Beaulieu2, L. Bessette3,
F. Morin4, D. Choquette1, B. Haraoui1, F. Abram5, J.-P. Pelletier1
1Osteoarthritis Res. Unit, Notre-Dame Hosp.,Univ. of Montreal
Hosp. Res. Ctr. (CRCHUM), Montreal, QC, Canada; 2Faculty of
Med., Univ. of Laval, Quebec, QC, Canada; 3Groupe de recherche
en rhumatologie et maladies osseuses, Sainte-Foy, QC, Canada;
4Ctr. de recherche musculosquelettique, Trois-Rivières, QC,
Canada; 5ArthroVision Inc., Montreal, QC, Canada
Purpose: An open-label 12-month pilot study evaluating the dis-
ease modifying effect of continuous treatment with celecoxib 200
mg daily compared to a modelized historical control cohort in the
treatment of knee osteoarthritis (OA).
Methods: The primary objective of this study was to evaluate, us-
ing magnetic resonance imaging (MRI), cartilage volume changes
in the medial compartment of the knee (femoral condyle and tibial
plateau) on subjects treated with celecoxib at 200 mg daily (99
patients were recruited; 78 completed the study) for 12 months
compared to a modelized historical control cohort (n=89), as ex-
pressed by percentage loss from baseline. Secondary outcomes
included other cartilage volume assessments including global and
lateral compartments as well as knee OA symptoms such as pain,
stiffness, and function, as assessed by the WOMAC questionnaire.
Safety of the medication was also assessed. The comparison be-
tween the two cohorts was evaluated by a multivariate linear
regression model.
Results: Cartilage volume loss was not reduced by celecoxib
when compared to a modelized historical cohort. Celecoxib pro-
vided clinically and statistically signiﬁcant improvement in symp-
toms for knee OA patients as shown by the WOMAC scores on
pain, stiffness and function. The safety data reported several minor
adverse events no different from those typically seen in a one-year
clinical trial.
Conclusions: Although celecoxib was demonstrated to be safe
and effective for knee OA symptom relief at a daily dose of
200 mg, it did not demonstrate a structural protective effect on
knee cartilage. Cohort modelization is an efﬁcient and unbiased
way to provide a comparator group for the assessment of novel
treatments when classic head-to-head randomized controlled trial
is not feasible.
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SHOCKWAVE PROMOTES OSTEOGENESIS OF BONE
MARROW STROMAL CELLS IN HIP NECROSIS
C.-J. Wang
Chang Gung Mem. Hosp. at Kaohsiung, Taiwan, Kaohsiung
Hsien, Taiwan
Purpose: Bone marrow stromal cells may play an important role
in hip necrosis. This in vitro study investigated the osteogenesis
effect of extracorporeal shockwave on bone marrow stromal cells
in hip necrosis.
Methods: Bone marrow stromal cells were harvested from bone
marrow cavity of six patients with hip necrosis. The specimens
were divided into four groups including the control, shockwave,
shockwave plus L-NAME and shockwave plus NOC18. The con-
trol group received no additional treatment. The shockwave group
received 500 impulses of shockwave at 14 Kv (equivalent to
0.18 mJ/mm2). The shockwave plus L-NAME group was pre-
treated with an inhibitor, L-NAME before shockwave treatment.
The shockwave plus NOC18 group consisted of the administration
of a promoter, NOC18 and application of shockwave. The evalu-
ation parameters included assessment of cell proliferation (MTT),
measurement of alkaline phosphatase level, analysis of VEGF,
BMP2, RUNX2 and osteocalcin on real time PCR and von Kossa
stain for mineralized nodules.
Results: Signiﬁcant increases of MTT, alkaline phosphatase,
VEGF, BMP2, RUNX2 and osteocalcin and more mature mineral-
ized nodules (Fig. 1) were observed after shockwave treatment as
compared to the control. Pre-treatment with L-NAME signiﬁcantly
The Results of MTT (Cell Proliferation), Alkaline Phosphatase Levels (mMol/ml),
VEGF, BMP-2, RUNX-2
Control Shockwave SW+L NAME NOC18
MTT 0.311±0.005 0.352±0.006 0.325±0.006 0.348±0.003 P1: <0.0001
(48 hrs) P2: 0.0566
P3: 0.0002
P4: 0.0496
Alkaline Phosphatase
Levels (mMol/ml)
(72 hrs) 1.537±0.152 2.442±0.156 1.996±0.138 2.438±0.042 P1: 0.001
P2: 0.0867
P3: 0.0065
P4: 0.003
VEGF 1 4.9±0.38 2.26±0.64 4.528±0.12 P1: 0.0154
P2: 0.0945
P3: 0.0252
P4: 0.0006
BMP2 1 1.57±0.18 0.83±0.12 1.46±0.09 P1: 0.0424
P2: 0.1499
P3: 0.0161
P4: 0.0016
RUNX2 1 1.6±0.17 0.93±0.03 1.97±0.19 P1: 0.0371
P2: 0.0918
P3: 0.0283
P4: 0.0065
OCN 1 2.03±0.3 0.93±0.03 2.73±0.29 P1: 0.0366
P2: 0.0918
P3: 0.0319
P4: 0.0134
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Figure 1
reduced the effects and the results were comparable to the con-
trol (Table 1). The addition of NOC18 signiﬁcantly enhanced the
effects of osteogenesis.
Conclusions: The results of the current study tested the hy-
pothesis that ESWT signiﬁcantly promotes osteogenesis of bone
marrow stromal cells. These innovative ﬁndings at least in part,
explain some of the mechanism of ESWT in hip necrosis.
332
EQUIVALENT EFFICACY OF A TOPICAL FORM OF
KETOPROFEN (KETUM® 2.5% GEL) AND ORAL
DICLOFENAC IN THE TREATMENT OF HAND
OSTEOARTHRITIS: RESULTS FROM ARTOPIK STUDY
S. Rozenberg1, P. Levan2, S. Kozma3
1Pitié-Salpêtrière Hosp., Paris, France; 2INSEP, Paris, France;
3Menarini Lab., Rungis, France
Purpose: Hand osteoarthritis (OA) is a common rheumatologic
disease, with an estimated prevalence of 38% for women and
24.5% for men, aged over 66 years. The objective of this study is to
compare the efﬁcacy and tolerability of a topical form of ketoprofen
(Ketum® 2.5% gel) versus oral diclofenac in the treatment of hand
OA.
Methods: This randomized, double-blind, double-dummy multicen-
tre clinical trial was conducted in France by 64 general physicians
between March 2007 and May 2008. Eligible patients included
men and women between 45 and 75 years old, with symptomatic
hand OA diagnosed according to the criteria of the American
College of Rheumatology and presenting with a base-line visual
analogue scale (VAS) score >40 mm and a Dreiser score ≥5.
Patients were randomly assigned to treatment with ketoprofen gel
plus placebo oral capsules, or placebo gel plus oral diclofenac
capsules (150 mg/d). Clinical assessments were performed 3 and
7 days after the initiation of the treatment. The primary endpoint
was deﬁned as the change of VAS scores ( VAS) between base-
line and last assessment. The analysis of the primary endpoint in
the per-protocol (PP) population was set as the primary analysis.
[-8mm to +8mm] was set as the equivalence interval (95% CI).
The full analysis set (FAS) and the PP populations were deﬁned
a priori in the statistical analysis plan. 61 patients were eliminated
patients), to compliance issues.
from the FAS population (n=395) due, for most of them (46
Abstract 332 – Table 1. Efﬁcacy results
Ketum® 2.5% gel (N=164) Diclofenac per os (N=170) Statistical analysis
Change of VAS score* at 7 days (mm) (primary endpoint) -33.2±21.0 -36.9±21.0 [ -1.1 ; 7.4 ]
conﬁdence interval of adjusted difference
Change of VAS score at 3 days (mm) -19.7±14.4 -21.3±15.5 0.427 (P value of ANCOVA)
Change of Dreiser score** at 7 days -6.0±4.4 -6.4±4.4 0.190 (P value of ANCOVA)
Change of Dreiser score at 3 days -3.6±3.1 -3.7±3.2 0.568 (P value of ANCOVA)
PGA on last assessment Very efﬁcient: 26.4% Very efﬁcient: 33.5% p=0.304 (bilateral Wilcoxon test)
Efﬁcient: 36.8% Efﬁcient: 31.8%
Moderalety efﬁcient: 27.0% Moderalety efﬁcient: 25.9%
Not efﬁcient: 9.8% Not efﬁcient: 8.8%
Pain auto-evaluation*** 31.2±8.7 29.5±8.9 p=0.078 (bilateral Wilcoxon test)
Therapeutic index**** (physician’s assessment) 2.86±1.00 3.09±0.97 p=0.033 (bilateral Wilcoxon test)
*Score from 0mm (no pain) to 100mm (maximal pain). **Score between 0 (no functional disability) and 30 (maximal functional disability). ***Area under the curve of
pain auto-evaluation from day 1 until day 7. ****Ratio of efﬁcacy/tolerability, comprised between 0,25 (worst ratio) and 4 (best ratio).
Results: 395 patients, predominantly females (74%), with a mean
age of 61 years were included. At base-line, mean VAS score and
Dreiser score were 70 mm and 12.5, respectively. Both treatment
arms were comparable for all the patients’ characteristics. In the
FAS population,  VAS scores at the end of the treatment [0,4mm
to 8,5mm] was slightly outside the equivalence interval. Whereas,
in the PP population (n= 334), the result of primary endpoint
was [-1,1mm to 7,4mm], demonstrating equivalence of efﬁcacy
between Ketum® 2.5% gel and diclofenac per os. Equivalence
was also shown for the following secondary efﬁcacy endpoints: 
VAS scores at 3 days,  Dreiser scores at 3 and 7 days, patient
efﬁcacy global assessment (PGA) and pain auto-evaluation (see
table 1). In terms of tolerability, there was no signiﬁcant difference
between both treatment groups (p=0.108).
Conclusions: This present study shows that, in the PP population,
Ketum® 2.5% gel and diclofenac per os are equivalent in terms of
efﬁcacy for the treatment of hand OA. These results support that
Ketum® could be an alternative therapy to oral NSAID treatments.
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CHALLENGES IN DESIGNING RANDOMIZED CLINICAL
TRIALS FOR CARTILAGE REPAIR: THE BST-CarGel
EXPERIENCE
A. Restrepo1, W.D. Stanish2, C.D. Hoemann3,
M.D. Buschmann4, M.S. Shive1
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Halifax, NS, Canada; 3Chemical Engineering Ecole
Polytechnique, Montreal, QC, Canada; 4BIOMed. and Chemical
Engineering Ecole Polytechnique, Montreal, QC, Canada
Purpose: To identify and discuss ﬁve of the challenges experi-
enced during the designing, planning and execution of a RCT for
cartilage repair, using the pivotal study for BST-CarGel® (a new
medical device being investigated for the repair of focal articular
cartilage lesions) as an example. To summarize some aspects of
the trial and of the preclinical work that preceded its design.
Methods: Five major challenges in the process of planning and
conducting a pivotal trial for cartilage repair processes were iden-
tiﬁed and summarized. The preclinical work as the basis to design
the trial is summarized. The basics of the currently ongoing inter-
national pivotal trial are presented, as well as a brief description
of the clinical use of the device.
Results: Major challenges were: Lack of regulatory trial historical
comparators for cartilage repair: There were almost no bench-
marks when the trial was designed. An FDA guidance was issued
only in July 07. Identiﬁcation of appropriate primary, secondary
and tertiary endpoints becomes difﬁcult. Lack of agreement on the
appropriate tools to measure outcomes: Pain as primary outcome
vs structure of the new tissue. No test presently is the gold stan-
dard for cartilage repair; patient relevant tests, designed for OA or
ligament reconstruction, based on subjective input are still used.
